Industry

Industry — chronic-care medical consumables

Convatec sells small, recurring, single-use products that patients use every day for the rest of their lives — wound dressings, ostomy pouches, urinary catheters, and insulin-pump infusion sets. The customer is a patient with a permanent condition; the buyer is usually a public payer or a hospital group; and the unit economics resemble a razor-and-blade business with regulatory moats. Volumes are tied to the slow, near-recession-proof growth of chronic disease, not to surgical procedure cycles, so the business is unusually defensive but also unusually exposed to reimbursement decisions in a handful of countries.

The big newcomer trap: this looks like "medical devices," but it is a consumables sub-industry whose returns are driven by patient-stickiness and reimbursement codes — not by capital equipment, not by big surgical innovation cycles. Read it that way.

1. Industry in One Page

Takeaway: the industry sells stickiness, not surgery. The patient never stops using the product — that recurring volume is the asset. Reimbursement is the throttle.

2. How This Industry Makes Money

The revenue engine is volume × code-based price × a small number of reimbursement gatekeepers, repeated forever per patient. That structure produces high gross margins (55-60%) because each pouch, dressing, or catheter is cheap to make at scale, and brand loyalty is sticky once a patient finds a body-fit that works. Where money concentrates is in the value-chain steps closest to the patient — formulation IP, manufacturing scale, and the home-delivery / nurse-support layer that locks in repeat ordering.

Two terms you'll see often:

• DMEPOS — Durable Medical Equipment, Prosthetics, Orthotics & Supplies. The US Medicare bucket that pays for ostomy and continence consumables.
• Skin-substitute / biologic dressing — engineered tissue (e.g., porcine placental matrix) used on chronic wounds; reimbursed per square centimetre under separate codes.

The economics that make this attractive: small absolute prices ($1-$30 per piece) make individual purchases nearly invisible to payers, while annual per-patient spend ($1,000-$5,000) is small relative to the alternative cost of complications. Gross margin sits 5-10 points above industrial-average med-tech because production is mature and inputs are commoditised polymers; the operating-margin spread between leaders and laggards is built almost entirely in the SG&A line — specifically in commercial productivity and home-delivery scale.

3. Demand, Supply, and the Cycle

Demand here is not cyclical — it is demographic. The user base only grows: more people aged 65+, more diabetes, more cancer survivors with stomas, more people surviving long enough to need continence support. Supply is constrained mostly by clean-room manufacturing capacity and regulatory approvals; capacity expansion takes 18-36 months and is hard to undo, which keeps industry pricing stable.

The "cycle" is a regulatory cycle, not an economic one. A code change in Baltimore (CMS) can do more damage in a quarter than a global recession would in a year. That is the single most important industry fact a generalist investor misses.

4. Competitive Structure

Each franchise is a separate competitive arena with its own #1, #2, #3 — there is no global "chronic-care" leader. The industry is concentrated within categories (top 3 typically take 60-80% share) but fragmented across the company-level league table because the categories rarely overlap fully. Convatec is one of only two listed pure-plays (with Coloplast); most peers are diversified med-tech holdcos where chronic-care is a slice.

The two biggest private players — Hollister and Mölnlycke — are large enough that excluding them from public-comp screens flatters the listed peer set's apparent share. Treat the listed-peer concentration table as an underestimate of true industry consolidation.

5. Regulation, Technology, and Rules of the Game

Regulation is the operating model of this industry, not a side risk. Three rule-makers do most of the work: CMS (sets US Medicare prices and decides which products even get reimbursed), the FDA (clears products and can issue Warning Letters that pause shipments), and the EU MDR (the 2021 European Medical Device Regulation, which forced re-certification of every device and quietly culled long-tail SKUs). Technology change matters here only when it changes the reimbursement code — automated insulin delivery (AID) is the current example.

The pattern: every meaningful "growth driver" and "headwind" in this industry traces back to a regulatory or reimbursement event, not a technology breakthrough or end-market boom.

6. The Metrics Professionals Watch

Generic ratios mislead here. EBITDA margins look low next to surgical-device peers because chronic-care players carry heavier sales infrastructure; ROCE looks low because home-services acquisitions sit on the balance sheet at goodwill. The metrics below are the ones that actually explain why one franchise compounds and another stalls.

If a sell-side note quotes only revenue growth and EBITDA, it is missing the industry's two most diagnostic numbers: Vitality Index (innovation reality) and equity cash conversion (whether the operating margin is real).

7. Where Convatec Fits

Convatec is one of two listed pure-play chronic-care consumables companies in the world (the other is Coloplast). It is the #2 in Ostomy and Continence behind Coloplast, a top-3 in Advanced Wound Care, and effectively the outsourced manufacturing platform for the global insulin-pump industry — a position that has no listed equivalent. It is mid-cap (~$4.1bn market cap) competing with mega-cap diversified med-tech and a much larger pure-play, which sets the strategic question: scale-up via category leadership, or be the acquired asset.

The chart shows the strategic dilemma in a single picture: Convatec sits in the same growth/margin neighbourhood as Coloplast, BDX, and Solventum but with a fraction of the equity value and a far smaller listed-peer free-float. The bull case is margin convergence to Coloplast (28% vs Convatec 22.3%); the bear case is that mid-cap pure-plays in chronic-care often end up acquired before they finish that journey.

8. What to Watch First

A short, observable checklist that tells you within a quarter whether the industry backdrop is moving for or against Convatec: